<DOC>
	<DOCNO>NCT03056040</DOCNO>
	<brief_summary>The purpose study ass ALXN1210 compare eculizumab adult patient PNH clinically stable eculizumab least 6 month</brief_summary>
	<brief_title>ALXN1210 Versus Eculizumab Adult Patients With Paroxysmal Nocturnal Hemoglobinuria ( PNH ) Currently Treated With Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>1 . Male female ≥18 year age 2 . Treated eculizumab PNH least 6 month prior Day 1 3 . LDH level ≤ 1.5 × ULN screen 4 . PNH diagnosis confirm documented highsensitivity flow cytometry 5 . Documented meningococcal vaccination 3 year prior , time , initiate study treatment . 6 . Female patient childbearing potential must use highly effective contraception start screen continue least 8 month last dose ALXN1210 7 . Willing able give write informed consent comply study visit schedule 1 . History bone marrow transplantation 2 . Body weight &lt; 40 kilogram 3 . History ongoing major cardiac , pulmonary , renal , endocrine , hepatic disease , opinion investigator sponsor , would preclude participation . 4 . Unstable medical condition ( eg , myocardial ischemia , active gastrointestinal bleed , severe congestive heart failure , anticipate need major surgery within 6 month randomization , coexist chronic anemia unrelated PNH ) 5 . Females pregnant , breastfeed positive pregnancy test screen Day 1 6 . Participation another interventional clinical study use experimental therapy within 30 day initiation study drug Day 1 study within 5 halflives investigational product , whichever great .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>